ATE550037T1 - Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen - Google Patents

Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen

Info

Publication number
ATE550037T1
ATE550037T1 AT05817101T AT05817101T ATE550037T1 AT E550037 T1 ATE550037 T1 AT E550037T1 AT 05817101 T AT05817101 T AT 05817101T AT 05817101 T AT05817101 T AT 05817101T AT E550037 T1 ATE550037 T1 AT E550037T1
Authority
AT
Austria
Prior art keywords
sars coronavirus
compositions against
sars
coronavirus
compositions
Prior art date
Application number
AT05817101T
Other languages
English (en)
Inventor
Meulen Jan Ter
Den Brink Edward Norbert Van
Kruif Cornelis Adriaan De
Jaap Goudsmit
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE550037T1 publication Critical patent/ATE550037T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05817101T 2004-11-11 2005-11-10 Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen ATE550037T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62777304P 2004-11-11 2004-11-11
EP04105684 2004-11-11
EP04106192 2004-11-30
EP05102117 2005-03-17
EP05107288 2005-08-08
PCT/EP2005/055876 WO2006051091A1 (en) 2004-11-11 2005-11-10 Compositions against sars-coronavirus and uses thereof

Publications (1)

Publication Number Publication Date
ATE550037T1 true ATE550037T1 (de) 2012-04-15

Family

ID=35747767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05817101T ATE550037T1 (de) 2004-11-11 2005-11-10 Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen

Country Status (9)

Country Link
US (1) US8106170B2 (de)
EP (1) EP1812067B1 (de)
KR (1) KR101255861B1 (de)
AT (1) ATE550037T1 (de)
AU (1) AU2005303758B2 (de)
CA (1) CA2582057C (de)
NZ (1) NZ553701A (de)
SG (1) SG159542A1 (de)
WO (1) WO2006051091A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
NZ580607A (en) 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
CA2579523C (en) * 2004-10-12 2016-04-12 Crucell Holland B.V. Atad3a-binding molecules for treatment, detection and prevention of cancer
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2007044695A2 (en) * 2005-10-07 2007-04-19 Dana-Farber Cancer Institute ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
US7728110B2 (en) 2006-05-19 2010-06-01 Amgen, Inc. Antibodies to SARS coronavirus
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US20110159001A1 (en) * 2008-01-17 2011-06-30 Institute For Research In Biomedicine CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF
EP2296551B1 (de) 2008-06-30 2016-04-20 Koninklijke Philips N.V. Spektrale ct
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (de) * 2010-04-07 2016-09-28 Agency For Science, Technology And Research Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112016029579A2 (pt) 2014-06-26 2017-08-22 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
WO2021148884A1 (en) * 2020-01-24 2021-07-29 Tychan Pte. Ltd. Anti-wuhan coronavirus antibodies
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP3872091B1 (de) 2020-02-26 2023-06-14 VIR Biotechnology, Inc. Antikörper gegen sars-cov-2
WO2021183195A1 (en) 2020-03-09 2021-09-16 1.Abcellera Biologics Inc. Anti-coronavirus antibodies and methods of use
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021205408A1 (en) * 2020-04-10 2021-10-14 Igy Immune Technologies And Life Sciences Inc. Igy immunoglobulins targeting coronavirus, methods of preparing same, and methods of using same
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
WO2021232041A1 (en) * 2020-05-09 2021-11-18 Baylor College Of Medicine N-acetylcysteine and glycine for treatment of covid-19 and post covid-19 symptoms
EP4149538A1 (de) 2020-05-11 2023-03-22 Janssen Pharmaceuticals, Inc. Sars-cov-2-impfstoffe
GB202007312D0 (en) * 2020-05-18 2020-07-01 Synthetic Vac Ltd Mimotope peptides of the spike protein from the sars-cov-2 virus
CA3180477A1 (en) * 2020-06-12 2021-12-16 Elizabeth Alexander Antibody therapies for sars-cov-2 infection
KR20230035346A (ko) 2020-07-06 2023-03-13 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
EP4175983A1 (de) 2020-07-06 2023-05-10 Flagship Pioneering Innovations VI, LLC Gegen sars-cov-2 gerichtete antigenbindende moleküle
CA3187008A1 (en) * 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
CN116194477A (zh) * 2020-08-06 2023-05-30 生物技术欧洲股份公司 冠状病毒s蛋白的结合剂
EP4204446A1 (de) 2020-08-26 2023-07-05 Flagship Pioneering Innovations VI, LLC Gegen sars-cov-2 gerichtete antigenbindende moleküle
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
EP3970798A1 (de) * 2020-09-18 2022-03-23 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Sars-cov-2-nanokörper
WO2022067020A1 (en) * 2020-09-24 2022-03-31 The Broad Institute, Inc. Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
JP2023549677A (ja) * 2020-11-06 2023-11-29 チョ ファーマ インコーポレイテッド 抗原およびその糖鎖操作抗体を含む免疫組成物
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
EP4370681A4 (de) * 2021-07-16 2025-11-19 Biocad Joint Stock Co Auf influenzavirus basierendes isoliertes rekombinantes virus
EP4388017A4 (de) 2021-08-20 2026-03-04 Christopher E Rudd Zusammensetzungen und verfahren für chimären antivirus-antigenrezeptor
CN113908264B (zh) * 2021-10-21 2023-06-23 中国人民解放军空军军医大学 基于噬菌体载体的新型冠状病毒疫苗及其制备方法
US11993644B2 (en) 2022-05-06 2024-05-28 Generate Biomedicines, Inc. Antigen binding molecules targeting SARS-CoV-2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
ES2237420T5 (es) 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
WO2002103012A1 (en) 2001-06-15 2002-12-27 Crucell Holland B.V. Chimaeric phages
FR2828405B1 (fr) 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
WO2004111081A2 (en) 2003-06-13 2004-12-23 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
EP1646645A1 (de) 2003-07-21 2006-04-19 Crucell Holland B.V. Antigene peptide des sars-coronavirus und anwendungen davon
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US7396914B2 (en) 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof

Also Published As

Publication number Publication date
KR101255861B1 (ko) 2013-04-17
EP1812067A1 (de) 2007-08-01
US8106170B2 (en) 2012-01-31
CA2582057C (en) 2015-08-11
WO2006051091A1 (en) 2006-05-18
CA2582057A1 (en) 2006-05-18
AU2005303758A1 (en) 2006-05-18
SG159542A1 (en) 2010-03-30
US20080014204A1 (en) 2008-01-17
AU2005303758B2 (en) 2011-04-28
NZ553701A (en) 2009-12-24
EP1812067B1 (de) 2012-03-21
KR20070083768A (ko) 2007-08-24

Similar Documents

Publication Publication Date Title
ATE550037T1 (de) Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ECSP088107A (es) Inhibidores de la proteasa ns3 del vhc
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008051477A3 (en) Hcv ns3 protease inhibitors
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
NO20082298L (no) Kaliumkanalinhibitorer
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
NO20070751L (no) Inhibitorer av HCV-replifikasjon
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
NO20084637L (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
NO20076405L (no) Anvendelse av 24-nor-UDCA
BRPI0612124A2 (pt) derivados de heteroarila para o tratamento de viroses